Kornimate/medical-research-clean huggingface dataset:
evaluate safety and efficacy of autologous bone marrow-derived endothelial progenitor cells in advanced liver cirrhosis

Conditions: Liver Cirrhosis

Summary: endothelial progenitor cells (epc) represent a small cellular population of bone marrow and peripheral blood cells. epcs are recruited into injured tissues and play an important role in regeneration and reparation. experimental and clinical data suggest that epcs have hepatoprotective activity and could improve liver regeneration during acute and chronic liver injury. the aim of this project is to evaluate the safety and therapeutic effects of autologous bone marrow-derived epcs, when administered through the hepatic artery of patients with advanced liver cirrhosis.


Eligibility criteria:
inclusion criteria: * liver cirrhosis (child-pugh 8 or above). * ability to sign informed consent exclusion criteria: * age \ 75 * variceal bleeding or severe infection within the past 30 days before screening * chronic encephalopathy preventing the ability to sign informed consent (it could be done by legal representant of the patient) and/or the ability to follow the study protocol * hepatocellular carcinoma (previous or current) * any current or previous malignancy (within 5 years before the inclusion) except "in situ" tumors or skin basal cell carcinomas * any severe extrahepatic disease during the past 30 days before the inclusion * any current decompensated chronic disease * any contraindication for the examinations of the clinical protocol (medullar aspiration, arteriography, hvpg measurement) * any other condition that could negatively affect the compliance with the protocol * pregnant or breast-feeding women * participation in a trial of an experimental drug or device within 30 days before screening
cctap: cognitive control training for treatment of aud-ptsd

Conditions: Alcohol Use Disorder; Post Traumatic Stress Disorder

Summary: the primary objective of this study is to evaluate the feasibility of the revised brain training program with individuals diagnosed with alcohol use disorder (aud) and post-traumatic stress disorder (ptsd).


Eligibility criteria:
inclusion criteria: * participant is a veteran and is enrolled in outpatient substance use disorder treatment within veteran affairs palo alto health care system * participant meets diagnostic and statistical manual of mental disorders-5 criteria for current alcohol use disorder and seeking treatment for alcohol use disorder * participant meets meet diagnostic and statistical manual of mental disorders-5 criteria for current ptsd * participant must be willing to perform daily home-based computer exercises for 6 weeks * participant must demonstrate mild cognitive deficit on neuropsychological tests at the screening visit * participant must be a fluent english speaker from the age of 12 * participant must have adequate sensorimotor capacity to perform the program, including visual capacity adequate to read from a ipad screen at a normal viewing distance, auditory capacity adequate to understand normal speech, and motor capacity adequate to control a touchpad exclusion criteria: * participant with diagnosis of an illness or condition with known cognitive consequences (e.g., schizophrenia, bipolar disorder, cancer, multiple sclerosis, traumatic brain injury, mental retardation or pervasive developmental disorder, epilepsy, parkinson's disease, delirium or dementia) * participant with active suicidal ideations as measured by the columbia-suicide severity rating scale (c-ssrs) * participant with problems performing assessments or comprehending or following spoken instructions * participant who has been treated within 5 years of the date of consent with a computer-based cognitive training program manufactured by posit science * participant with current severe traumatic brain injury * participant with any type of dementia * participant with any type of mental retardation * participant with limited ability to speak/read/write/understand english
persea americana for total health (path)-2

Conditions: Overweight and Obesity

Summary: the goal of this clinical trial is to learn about the effects of avocado consumption on gastrointestinal health in adults with overweight and obesity. the main questions is aims to answer are: how does avocado consumption affect the gut microbiome? how does avocado consumption affect thinking? are there connections between the microbiome and cognition? participants will be asked to eat provided meals with and without avocados for three 4-week periods. at the end of each 4-week period, participants will be asked to provide stool samples and complete computer games that assess thinking and memory.


Eligibility criteria:
inclusion criteria: * participants must be between the ages of 25 and 74 years old * bmi ≥ 25 kg/m2 * ability to drop off fecal sample within 15 minutes of defecation * 20/20 or corrected vision exclusion criteria: * avocado allergy or intolerance * food allergies or intolerances * prior diagnosis of liver or gastrointestinal disease (primary biliary cirrhosis or gallbladder disease, chronic constipation, diarrhea, crohn's disease, celiac disease, ulcerative colitis, irritable bowel syndrome, diverticulosis, stomach or duodenal ulcers), diabetes, hepatitis, hiv, or cancer * women that are pregnant, have given birth in the previous 12 months or are lactating * individuals that smoke, use tobacco, abuse drugs, or consume \> 2 alcoholic beverages per day. * \> 5% weight change in the past month or \> 10% change in the past six months * oral antibiotics during the previous 6 weeks. * currently taking lipid-lowering medications, oral hypoglycemic agents, or insulin. * history of malabsorptive or restrictive bariatric surgeries (e.g., gastric bypass, sleeve gastrectomy, adjustable gastric band) or gall bladder removal surgery. * are unable to consume the experimental meals/snacks. * allergic to latex * concurrent enrollment in another dietary, exercise, or medication study

Keywords: avocado gastrointestinal microbiome bile acid profile inflammation thinking glycemia
gepheral: clinical validation of the genotypic diagnosis of hiv-1 resistance to raltegravir by parallel analysis of the genotype and phenotype profiles of resistance

Conditions: HIV-1 Infected Patients; Fold-change Resistance; Resistance Mutations

Summary: the purpose of this study is to correlate the different patterns of resistance mutations observed in vivo in patients failing ral treatment with the fold-change resistance determined by the phenotypic assay.

the secondary objectives are, as follows: * to establish standardised genotypic assay for the hiv-1 pol gene region (region of interest, sensitivity, mutations involved as primary or compensatory changes, role of polymorphism present at baseline). * to reach consensus on the algorithm interpretation of in house ex-vivo genotypic evaluations. * to assess the genetic changes in ral-failing patients under continuous drug pressure or drug discontinuation (dynamics of the reversion of resistance mutations). * to evaluate in ral resistant hiv-1 variants the changes in replication capacity (rc) (baseline vs. following-timepoints). * to evaluate the immunological and virological trend associated with a raltegravir-regimen failure.

Eligibility criteria:
inclusion criteria: * adult (at least 18 years of age) treatment-experienced, hiv-infected subjects of either sex and of any race, failing to a ral-containing regimen will be enrolled in the study exclusion criteria: * none

Keywords: hiv-1 infected patients raltegravir regimen genotypic evaluations phenotypic evaluations
nutrition and lifestyle behaviour peer support program among malaysian adults with metabolic syndrome (persuade)

Conditions: Metabolic Syndrome X; Nutritional and Metabolic Diseases; Health Behavior

Summary: the outlook of a community-based intervention targeting nutrition and lifestyle behaviour modification among adults with metabolic syndrome (mets) has not been fully explored. the primary aim of this study (persuade) is to evaluate the effect of the peer support intervention on the clinical outcomes mets components followed by improvements in the participants' dietary practices, physical activity levels and lifestyle behaviours. the program constructed using information obtained from the published clinical and dietary guideline in malaysia.

aim: to develop and assess a three-month, group-based community peer support program for malaysian adults with mets. method: the persuade module will be constructed using the health belief model (hbm) to address relevant health messages from the appropriate guidelines and recent literature evidence on mets among malaysian adults. following that, a minimum sample of 96 malaysian adults with mets will be randomised, either to the control group, who will receive one-time standard nutrition and lifestyle advice or the intervention group, who will participate in a three-month peer support program using the persuade module. the participants will be followed up for three months post-intervention with data collection scheduled at baseline, 3-month and 6-month. persuade is thoroughly designed using the current available guidelines informed with gathered inputs on motivations and barriers towards healthy lifestyle among malaysians. the program aims to improve the clinical outcomes of mets component among participants of the intervention group, besides the impact of the peer support intervention on the dietary practices, physical activity levels and lifestyle behaviours of those participants. the successful outcome of this study can be an initiator for policy makers to encourage more rigorous promotion of such community-based programmes in the country.

Eligibility criteria:
inclusion criteria: 1. physically healthy men and women who are ≥ 18 years old. 2. literate with a fair command of bahasa melayu and/or english. 3. metabolic syndrome status confirmed according to harmonised criteria. 4. willing to attend weekly peer gathering sessions. exclusion criteria: 1. pregnant, lactating or intend to become pregnant during the study period. 2. diagnosed with type 1 diabetes mellitus (t1dm) 3. any predisposing condition compromising the quality of life or ability to participate according to protocol. 4. reported severe complications (chronic heart disease, cerebrovascular disease, diagnosed hiv/aids, cancer, emphysema, chronic liver or kidney disease) that would affect the participants' ability to follow the participation in peer activity.
chinese translation and validation of the 8-item contact lens dry eye questionnaire (cldeq-8)

Conditions: Contact Lens; Questionnaire; Contact Lens Discomfort

Summary: this is a cross-cultural adaptation, evaluation and validation study of the 8-item contact lens dry eye questionnaire (cldeq-8) among soft contact lens wearers in china.

the aim of this study is to translate the 8-item contact lens dry eye questionnaire (cldeq-8) into chinese and evaluate its validity, and reliability among soft contact lens wearers in china. one hundred and thirty-four chinese soft contact lens wearers will be included in the study. subjects are required to complete the chinese version of the 8-item contact lens dry eye questionnaire (c-cldeq-8) on paper before eye examinations. a subgroup of 50 participants will be asked to complete c-cldeq-8 twice to evaluate the repeatability.

Eligibility criteria:
inclusion criteria: 1. age between 18-60 2. native chinese citizens with chinese as first language 3. wearing history with spherical disposable scl (daily disposable, 2 weeks, or monthly disposable) for a least 1 months; 4. willing to sign informed consent exclusion criteria: 1. any extended wear of scls, including wearing toric or multi-focal scls 2. use scl for monovision correction 3. having clinically significant anterior segment abnormalities (including iritis and infection of the eye, lids, or ocular adnexa) 4. having ocular or systemic disease that would preclude scl wearing 5. best corrected visual acuity of less than 0.8 in either eye 6. history of refractive or other types of corneal surgeries 7. having eyelid abnormalities or functional ocular disorders that would induce relevant discomfort. 8) having congenital or systemic conditions that would limit the capacity to answer the questionnaire

Keywords: the 8-item contact lens dry eye questionnaire cldeq-8 contact lens discomfort questionnaire chinese translation and validation
effects of leptin replacement in children

Conditions: Obesity; Metabolic Syndrome; Diabetes

Summary: to assess the endocrine and immune effects of leptin replacement in leptin-deficient children, from a consanguineous family. the hypothesis is that leptin replacement will have significant effects on endocrine function.

the proposed study of the treatment of a child with congenital leptin deficiency will permit to elucidate key aspects of human endocrine function, and will give new insights on the role of leptin in human endocrine regulation.

Eligibility criteria:
inclusion criteria: * children with a functional leptin gene mutation from a consanguineous turkish family. only one leptin-naïve child from this family is alive and eligible. exclusion criteria: * n/a

Keywords: congenital leptin deficiency obesity metabolic syndrome diabetes
a pilot study to assess the safety and efficacy of oral pth (1-34) in the treatment of hypoparathyroidism

Conditions: Hypoparathyroidism

Summary: this is an observational, international, open label, pilot study to evaluate the safety, tolerability and efficacy of an oral pth (1-34) preparation produced by entera bio in adult hypoparathyroid volunteers.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of primary hypoparathyroidism for more than 1 year. * currently taking \>1.0 grams of calcium/day with a correlate alpha d3 dose. * 25(oh)d levels ≥ 20 ng/ml. * signed informed consent. * bmi 18 - 30 kg/m2, inclusive. * full blood count should be within the reference range as per who criteria. minor abnormalities will be assessed by the principle investigator and after discussion with sponsor patients may still be entered if these are felt to be of "no clinical importance". abnormalities due to hypoparathyroidism related are acceptable and will not constitute exclusion. * patients with significant liver function impairment (liver enzymes above x3 the upper limit of normal range as per who criteria) will be excluded. * subjects able to adhere to the visit schedule and protocol requirements. exclusion criteria: * haemoglobin \<12 g/dl (females)/ \<13gm/dl (males) \[lower limit of reference range 12-15 \& 13-17\] * impaired renal function * impaired liver function; alt \>38 international units per liter (iu/l), or alp\>125 iu/l * significant drug or alcohol abuse as assessed by the principal investigator * allergy to soy bean products * presence of kidney or urinary tract stones * concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study medication. * treatment with any investigational product within the last 30 days, enrollment or intention to enroll in any active study involving the use of investigational devices or drugs. * presence of any other condition or circumstance that, in the judgment of the investigator, might increase the risk to the patient or decrease the chance of obtaining satisfactory data to achieve the objectives of the study. * active infections * pregnancy or suspected pregnancy. female subjects must have a negative serum pregnancy test at screening and be willing and able to use a medically acceptable method of birth control (reliable use of oral contraceptive, non-hormonal intrauterine device with condom, or diaphragm with condom, or condom with spermicide) from the screening visit through the study termination visit or declare that they are abstaining from sexual intercourse from the screening visit through the study termination visit or are surgically sterile (have undergone bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or post-menopausal. postmenopausal women are defined as women with menstruation cessation for 12 consecutive months prior to signing of the informed consent form.
does cold provocation increase brown adipose tissue volume?

Conditions: Brown Adipose Tissue, Human

Summary: about 28 healthy subjects are randomized to 1 hour/day of coldprovocation or to the best of ability to avoid feeling cold, for 6 weeks. basal metabolic rate and magnetic resonance (for determination of brown adipose tissue volume) imaging are performed before and after the study.


Eligibility criteria:
inclusion criteria: healthy subjects - exclusion criteria: any significant disease, ot other conditions that interferes with magnetic resonance imaging -

Keywords: brown adipose tissue, human
readmission risk of patients with heart failure.

Conditions: Chronic Heart Failure

Summary: heart failure (hf) is a frequent, serious, and costly chronic disease: it leads to 150,000 hospitalizations each year in france at a cost of 525 million euros. it is estimated that 20-40% of these hospitalizations are preventable by known interventions: home telemonitoring, care coordination, therapeutic intensification and therapeutic education. but these interventions only work if patients at high risk of rehospitalization are targeted to individualize management. in these patients, the risk of rehospitalization depends on clinical, biological, socioeconomic, care pathway, and location-related data. existing predictive tools perform poorly due to three important limitations: non-use of unstructured clinical data, lack of integration of multimodal data, and weakness of the algorithmic approach. the objective is to design and validate a predictive algorithm for the risk of rehospitalization in heart failure patients, using multiple data sources


Eligibility criteria:
inclusion criteria: * all consecutive adults * admitted to montpellier university hospital in 2017-2020 * for heart failure exclusion criteria: - age \< 18 years

Keywords: heart failure prediction personnalized medicine
the effect of energy drinks consumption on acute physiological and psychological responses of israeli arab adolescents

Conditions: Energy Drinks

Summary: quasi-experiment and cross-sectional study, six-arm design protocol will be carried out. the study will be conducted under the declaration of helsinki. the current study will assess the effects of eds consumption on the physiological and psychological responses of israeli arab adolescents. these effects will also be examined in association with the adolescent's plasma metabolite profiles. the study has five specific aims: (1) to assess the effects of ed consumption with or without a meal, on israeli arab adolescents glucose levels by using mixed meal tolerance test (mmtt) (2) to assess the effect of ed consumption with or without a meal on their blood pressure (3) to evaluate the association between ed consumption per day by the israeli arab adolescents and their nutritional status and habits (4) to examine for possible associations between israeli arab adolescents psychological status (i.e. mood and anxiety) and ed consumption per day (5) to examine for possible associations between ed and caffeine consumption and plasma metabolite profiles and, the subject's psychological status.


Eligibility criteria:
inclusion criteria: * healthy * israeli arab adolescents * aged 14.5-17.5 years exclusion criteria: * diabetes * hypoglycemic episodes * coronary heart disease, cardiac arrhythmia, secondary hypertension, structural heart lesions * hepatic or renal disorders * autonomic neuropathy * epilepsy * obstructive sleep apnea * migraines * caffeine intolerance * eating disorders or other mental disorders or those with prescribed psychiatric medications

Keywords: energy drinks (eds) blood pressure (bp) glucose tolerance metabolite profiles mood anxiety
immediate effects of postural repositioning on voice production tasks in seated individuals with acquired dysarthria:

Conditions: Acquired Dysarthria (Finding)

Summary: to determine the effectiveness of a single 10-min postural repositioning session on the maximum phonation duration in individuals with acquired dysarthria.

the impact of dysarthria goes beyond communication. however, there have been no clear directives guiding clinical practice to date, and despite increasing evidence directing treatment, research remains limited and predominantly consists of case studies or case series. despite the importance of postural control in voice production, the effects of postural alignment on speech production efficiency are either little investigated or not at all explored in the dysarthric population. this study determined the effectiveness of a single 10-min postural repositioning session on the maximum phonation duration (mpd) in individuals with acquired dysarthria.

Eligibility criteria:
\*\*participants with dysarthria inclusion criteria * sustained a stroke or traumatic brain injury * diagnosed with dysarthria * impaired postural control following a neurological injury * are approaching the end of intensive rehabilitation or have finished intensive rehabilitation * express a desire to participate in the research * have the capacity to read. exclusion criteria * had any cognitive impairment that could prevent them from understanding directives or from expressing their opinion about their posture a neurologist clinically assessed the cognitive function of pwds \*\*control participants * never diagnosed with dysarthria or any other voice impairment * no comorbidities. * no breathing deficits (e.g., asthma, chronic obstructive pulmonary disease) * no pathologies in the spinal cord, spinal column, or thoracic cage that could prevent them from freely moving their trunk * no neurological or cardiac problems.

Keywords: acquired dysarthria corrected seated posture maximum phonation duration electromyographic patterns
china-administration of nicorandil group（change）

Conditions: Myocardial Infarction; Percutaneous Coronary Intervention; Nicorandil

Summary: we compared the infarct size in st-segment elevation myocardial infarction (stemi) patients undergoing primary percutaneous coronary intervention (pci) treated by nicorandil before and after the reperfusion with those standard therapy treated by pci

the aim of this study was to evaluate the efficacy and safety of nicorandil in improving myocardial infarct size in patients with acute myocardial infarction through a multi-center, prospective, randomized, double-blind and parallel-controlled clinical study, providing evidence-based support for the optimization of pci treatment strategies. the primary objective of the study was to compare whether the effect of nicorandil in combination with pci was significantly better at reducing the myocardial infarct size than that of pci alone in ami patients.

Eligibility criteria:
inclusion criteria: 1. acute st-t elevation mi patients (\<12h) 2. undergoing emergency pci； 3. subject has read and signed a written, informed consent form. exclusion criteria: 1. sbp\<80mmhg； 2. lm stenosis 3. aortic dissection； 4. ami (\<6 month) 5. pci或cabg (\<6 month) 6. already under the treatment of nicorandil； 7. contraindicated or intolerable to nicorandil 8. severe adverse effects to cmr or mri； 9. currently (or within one month) participating in another new drug trial.； 10. pregnant or lactation period； 11. severe somatic disease preventing the participant from completing the trial, or based on the discretion of the investigators, the patient is incapable of participating; individuals with abnormal laboratory test results and/or clinical manifestations rendering them unsuitable to participate as judged by the investigators;

Keywords: cardiac magnetic resonance; infarct size